Current Analysis: Elekta (EKTAF)

TalkMarkets Episode IX219 Monday 8/12/24 Elekta AB (EKTAF) Health Care Sector

Sweden-based Elekta provides clinical solutions for treating cancer and brain disorders worldwide, including stereotactic radiosurgery and brachytherapy.

 

The company's installed base of more than 5,000 linear accelerators, GammaKnife and Unity platforms, and software is used in more than 6,000 hospitals globally.

 

The company's sales are evenly distributed across geographies, with North and South America accounting for 29%; Europe, the Middle East, and Africa accounting for 37%; and Asia-Pacific contributing the remainder.

The company was incorporated in 1972 and is headquartered in Stockholm.

 

Three key data points gauge Elekta or any dividend paying firm.

 

The key three are:

 

(1) Price

(2) Dividends

(3) Returns

 

Those three keys also best tell whether any company has made, is making, and will make money.

 

EKTAF Price

 

Over the past year, Elekta share price fell just about 24.4% from $8.22 to $6.13 as of Friday’s market close.

 

If Elekta shares trade in the range of $5.00 to $15.00 this next year, their recent $6.13 share price might rise to $6.60 by next year. Of course, EKTAF price could also drop about the same $0.47 estimated amount, or more.

 

My $0.47 upside just under the average of annual EKTAF share price gains over the past two years.

 

 

EKTAF Dividend

 

Elekta has paid semi-annual variable dividends since November, 2014. The most recent $0.1123 Monthly dividend was declared August 1st for shareholders of record September 6th and the dividend is payable September 12th. The forward looking $0.2246 annual dividend yields 3.66% at Friday’s closing price.

 

EKTAF Returns

 

To put it all together, an $0.695 estimated one year gross gain per share shows up when adding EKTAF’s  $0.2246 annual dividend to the estimated price upside of $0.4704, equalling $0.695.

 

A little over $1000 buys 163 shares at their $6.13 per share price.

 

A $10 broker fee (if charged), paid half at purchase and half at sale, might take about $0.06 per share out of the $0.695 annual, gross-gain to reveal a net gain of $0.635 X 163 shares = $103.50 for about a 10.4% estimated net gain on the year.

 

Furthermore, the $36.60 annual dividend income from $1K invested is just under 6 times Elekta’s $6.13 single share price. By these numbers, Elekta AB may be an ideal dividend dog.

 

You might choose to pounce on EKTAF. It is an 52 year-old semi-annual dividend-paying Stockholm-based Health Care Equipment firm with a near 10 year record paying  semi-annual dividends.

 

The exact track of EKTAF future price and dividend will entirely be determined by market action.

 

Remember the true value of any stock is best realized through personal ownership of shares.


More By This Author:

Current Analysis: Choice Properties REIT
Current Analysis: Flagship Communities REIT
Current Analysis: Modiv Industrial

Disclaimer: This and other personal blog posts are not reviewed, monitored or endorsed by TalkMarkets. The content is solely the view of the author and TalkMarkets is not responsible for the content of this post in any way. Our curated content which is handpicked by our editorial team may be viewed here.

Comments